Uppsala Reports editor
@UMCGlobalSafety
Real-world data is a rich source of evidence for pharmacovigilance, but there are challenges yet to be faced before unlocking its true potential as a resource.
Real-world data, or observational data collected during routine clinical care, could be a valuable source of evidence in pharmacovigilance. However, there are still hurdles to overcome before it can deliver on that value.
In the latest episode of the Drug Safety Matters podcast, Federica Santoro and Patrick Ryan from Johnson & Johnson discuss the challenges of using real-world data for patient safety and how this resource may be harnessed for pharmacovigilance through some ‘proof of concept’ projects such as OHDSI and EHDEN.
Like what you hear? Then subscribe to the podcast by visiting the Drug Safety Matters website.
Uppsala Reports editor
@UMCGlobalSafety
An Australian research team is using artificial intelligence to improve the safe dosing of unfractionated heparin, a high-risk drug linked to serious side effects.
30 March 2026
Analysis of paired reports from the Norwegian ADR Registry suggests merging consumer and healthcare professional accounts of the same adverse event may improve causality assessment
19 August 2026
Complementary medicines are widely used and often perceived as safe, yet high doses, product stacking, and unclear labelling can quietly increase the risk of harm.
07 April 2026